Neutral
ProShare Advisors LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 9.3% in the fourth quarter, according to its most...
Bullish
Boston Scientific has invested $1.5 billion in MiRus LLC for an approximately 34% equity stake, securing an exclusive option to acquire the MiRus TAVR...
Neutral
Baird has reiterated an Outperform rating on Boston Scientific (BSX) but lowered its price target to $75 from $78, following the company's re-entry in...
Bullish
Boston Scientific Corp. remains a significant player in the medical technology sector, focusing on minimally invasive cardiovascular and interventiona...
Bullish
Boston Scientific's FRACTURE IDE trial for its SEISMIQ 4CE Coronary IVL Catheter met its primary safety and effectiveness endpoints, showing 93.3% fre...
Bullish
Boston Scientific Corp (BSX) shares rose 2.1% in premarket trading after the company announced a $2 billion accelerated share repurchase agreement. Th...
Bullish
Boston Scientific's shares rose after the company announced a $2 billion accelerated share repurchase agreement, part of a larger $5 billion authoriza...
Boston Scientific (NYSE: BSX) has initiated a $2 billion accelerated share repurchase (ASR) program with JPMorgan Chase Bank, as part of its existing ...
Bullish
Boston Scientific (NYSE: BSX) has initiated a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, as part of its existin...
Neutral
Boston Scientific (NYSE: BSX) has announced a $1.5 billion investment for an approximately 34% equity stake in MiRus LLC, a company developing proprie...
Bullish
Boston Scientific reported Q1 2026 adjusted EPS of $0.80 on revenue of $5.20 billion, exceeding estimates, and revenue growth of 11.6% year over year....
Bullish
This article examines Boston Scientific Corp. (NYSE: BSX) following its recent quarterly earnings and ongoing developments in its medical device portf...
Bullish
Mike Archibald, a vice-president and portfolio manager at AGF Investments Inc., remains bullish on the U.S. economy, especially after a strong first-q...
Neutral
FMR LLC significantly reduced its holdings in Boston Scientific Corp. (BSX) by over 21.5 million shares in Q1 2026, indicating a strategic portfolio a...
Neutral
Boston Scientific Corp. stock has experienced a sharp decline recently, trading around the mid-$50s, which has reignited discussions about its valuati...
Neutral
Boston Scientific Corp. (BSX) shares recently hit a new 52-week low of $55.94 following analyst downgrades despite a modest quarterly beat. The stock ...
Neutral
Boston Scientific Corporation (NYSE:BSX) has received a "Moderate Buy" consensus recommendation from twenty-six analysts, with an average 1-year targe...
Neutral
Boston Scientific's 2026 Annual Meeting highlighted its strong 2025 performance, including $20 billion in net sales and over $2 billion invested in R&...
Bullish
Boston Scientific Corporation (BSX) is considered a top medical device stock, despite recent price target cuts from Argus and Truist. Analysts maintai...
Neutral
Calamos Wealth Management LLC decreased its stake in Boston Scientific Corporation by 24.4% in the fourth quarter, reducing its holdings to 117,214 sh...